Abraham Lee's Biography

Abraham Lee, Chancellor’s Professor, Biomedical Engineering & Director, Center for Advanced Design & Manufacturing of Integrated Microfluidics, University of California-Irvine

Abraham (Abe) P. Lee is Chancellor’s Professor of Biomedical Engineering (BME) and MAE at the University of California, Irvine (UCI). He served as department chair for BME from 2010-2019. He is currently Director of the NSF I/UCRC “Center for Advanced Design & Manufacturing of Integrated Microfluidics” (CADMIM). Dr. Lee served as Editor-in-Chief for the Lab on a Chip journal from 2017-2020. Prior to UCI, he was Senior Technology Advisor at National Cancer Institute (NCI), Program Manager in the Microsystems Technology Office at DARPA (1999-2001), and a group leader with Lawrence Livermore National Lab (LLNL). Dr. Lee’s current research focuses on integrated microfluidic systems for precision medicine including liquid biopsy, microphysiological systems, cell engineering, and immunotherapy. His research has contributed to the founding of several start-up companies. He is inventor of over 60 issued US patents and is author of over 130 journals articles. Professor Lee was awarded the 2009 Pioneers of Miniaturization Prize and is fellow of the National Academy of Inventors (NAI), the American Institute of Medical and Biological Engineering (AIMBE), the Royal Society of Chemistry (RSC), the American Society of Mechanical Engineering (ASME), the International Academy of Medical and Biological Engineering, and the Biomedical Engineering Society (BMES).

Circulatory System on a Chip -- From in vitro to in vivo, From Single Cell to Microphysiological Systems

Tuesday, 8 October 2019 at 16:30

Add to Calendar ▼2019-10-08 16:30:002019-10-08 17:30:00Europe/LondonCirculatory System on a Chip -- From in vitro to in vivo, From Single Cell to Microphysiological SystemsSELECTBIOenquiries@selectbiosciences.com

The circulatory system is a critical physiological process of the human body that maintains homeostasis by balancing biological parameters by the delivery and removal of nutrients/waste and fighting off invading pathogens. Through the advancement of microfluidics technologies, we have enabled the automation of biological fluids delivery through physiological vasculature networks that mimic the physiological circulation of the human body. The critical bottleneck is to engineer the microenvironment for the formation of 3D tissues and organs and to also pump and perfuse the tissue vascular network for on-chip microcirculation. On the other hand, microfluidics play an important role in the recent advances in liquid biopsy, an emerging technique that analyzes biological samples such as blood for the detection of biomolecules or cells that are indicative of disease or physiological state. Specifically, liquid biopsy has become a promising technology to isolate and target rare cells such as circulating tumor cells (CTCs) in body fluids thanks to many of these microfluidic cell sorting techniques. This advent of microfluidic liquid biopsy provides an in vitro snap shot into the patient’s physiological status via the in vivo circulation that enables one to monitor disease state and progression for diagnosis and prognosis. A key bottleneck is to identify the critical subpopulation of cells, often at single cell resolution among billions of cells in circulation. Along with the aforementioned in vitro on-chip perfused vascularized tissue platforms, these two technologies go hand-in-hand to connect in vitro screening to in vivo screening with great potential in the development of personalized medicine. Ultimately this is the microfluidic maintenance of physiological equilibrium, or ‘microfluidic homeostasis.'

Add to Calendar ▼2019-10-07 00:00:002019-10-09 00:00:00Europe/LondonLab-on-a-Chip and Microfluidics 2019: Emerging Themes, Technologies and Applications Track "A"SELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors